Press RELEASE
16 may 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, HONG KONG, JAPAN, CANADA, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE ANNOUNCEMENT, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE IN VIOLATION OF THE APPLICABLE RULES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF SANIONA.
Saniona AB (publ) (“Saniona” or “Bolaget”) (Nasdaq First North-ticker: SANION) intends to undertake a directed new share issue of up to 25-35 million SEK (the”rights Issue”). The potential rights Issue is targeted at Swedish and international institutional investors and, among other things, subject to the board of directors of Saniona (“the Board”) adopts a shares after the implementation of the accelerated bookbuilding-procedure that will be implemented by Pareto Securities AB (“Pareto Securities“) and Translution Capital A/S (“Translution Capital“).
The subscription price for the shares and the total number of shares to be issued in the rights Issue will be determined through a bookbuilding-procedure. Bookbuilding procedure will commence no earlier than there is a 17.31 (CET) on 16 may 2017 and be completed before the Nasdaq First North opening 17 may 2017. The minimum order will be set to the number of shares, corresponding to 100 000 euro. Bookbuilding-procedure, if the Company so decides, be shortened or extended and can be terminated at any time for any reason whatsoever.
The reason for the rights Issue is to increase the buffer to allow for additional flexibility in the Company’s current business plan in the face listflytten to the Nasdaq Stockholm is expected to occur during 2017.
The reason to deviate from the shareholders ‘pre-emptive rights in a directed share issue is to broaden the ownership base and to a targeted new share issue means lower costs and a faster process, which combined with sufficient strength suggests that it is in the Company’s and the shareholders’ interest to do a share issue, with deviation from the shareholders ‘ preferential rights.
Pareto Securities has been appointed as the Sole Manager and Joint Bookrunner and Translution Capital has been appointed Joint Bookrunner in connection with the rights Issue.
For more information, please contact:
Thomas Feldthus, executive vice president and CFO, Saniona. Mobile: +45 2210 9957, E-mail: tf@saniona.com
This information is such information that Saniona AB (publ) is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on 16 may 2017 there is 17:31 CET.
About Saniona:
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and pain management. The company has an extensive portfolio of potential drug candidates in preclinical or clinical Phase. The research is focused on the ion channels that constitute a unique class that allows for and controls the passage of ions in cell membranes. The company has partnered with Boehringer Ingelheim GmbH. Proximagen Ltd., Productos the medix, S. A de S. V and Luc Therapeutics. Saniona is based in Copenhagen where the company has a forskningssite of high international class. Saniona is listed on Nasdaq First North Premier and has approximately 5,000 shareholders. Pareto Securities is the Certified Adviser of Saniona. The share is traded under the ticker SANION. Read more on
www.saniona.com
.
IMPORTANT INFORMATION
Release, publication or distribution of this press release may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and abide by such legal restrictions. This press release does not constitute an offer of, or invitation to acquire or subscribe for, any securities in the Company in any jurisdiction.
This press release does not constitute an offer to purchase securities in the united states. The securities mentioned herein may not be sold in the united states without registration under the applicable U. S. Securities Act of 1933 or without the application of an exemption from such registration. Copies of this notice may not be made in and may not be distributed or sent into the united states, Australia, New Zealand, Hong Kong, Japan, Canada, Singapore or south Africa or any other jurisdiction where the announcement, publication or distribution of this information would be in violation of the applicable rules.
This press release is not a prospectus within the meaning of Directive 2003/71/EC, as amended by Directive 2010/73/EU. The company has not authorised any offer to the public of shares or rights in any member state of the EEA and no prospectus has been developed or will be developed in connection with the directed share issue.
20170516 – PR – Private Placement – ENG
